Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients

Journal of Clinical Pharmacology

Volumn 53, Issue 3, 2013, Pages 264-275

  McCune, Jeannine S ^a,b   Baker, K Scott ^b,c,d   Blough, David K ^a,b   Gamis, Alan ^e   Bemer, Meagan J ^b   Kelton Rehkopf, Megan C ^b   Winter, Laura ^d   Barrett, Jeffrey S ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e CHILDREN S MERCY HOSPITAL   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Busulfan; Hematopoietic cell transplant; Pediatric; Pharmacokinetics; Prescribing patterns; Therapeutic drug monitoring

Indexed keywords

BUSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALBERS SCHOENBERG DISEASE; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BONE MARROW DEPRESSION; CELL THERAPY; CHILD; CHRONIC MYELOID LEUKEMIA; COMBINED IMMUNODEFICIENCY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; GROUPS BY AGE; HEMATOPOIETIC CELL; HISTIOCYTOSIS; HODGKIN DISEASE; HUMAN; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKOCYTE DISORDER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OUTCOME ASSESSMENT; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRESCHOOL CHILD; PRESCRIPTION; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SICKLE CELL ANEMIA; SOLID TUMOR; THALASSEMIA;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ALKYLATING AGENTS; AREA UNDER CURVE; BUSULFAN; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84877859573     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270012447196     Document Type: Article

References (39)

1. Deeg HJ, Maris MB, Scott BL, Warren EH. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia. 2006;20(10):1701- 1705.
2. McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009;5(8): 957-969.
3. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89(8): 3055-3060.
4. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87(12):4979-4989.
5. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16(1): 31-42.
6. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28(11):1013-1018.
7. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17(2):225-230.
8. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25(1):55-61.
9. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30(3): 167-173.
10. Schechter T, Finkelstein Y, Doyle J, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(3):307-314.
11. Baker KS, Bostrom B, DeFor T, Ramsay NK, Woods WG, Blazar BR. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Bone Marrow Transplant. 2000; 26(6):607-614.
12. Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des. 2008;14(20):1936-1949.
13. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. IV busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004;33(10):979-987.
14. Shaw PJ, Nath C, Berry A, Earl JW. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages. Bone Marrow Transplant. 2004;34(3):197-205.
15. Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood. 2010;115(22):4597-4604.
16. Wall DA, Chan KW, Nieder ML, et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010;54(2):291-298.
17. Dalal J, Neville KA. Busulfan in children: impact of development on dose-exposure-response relationship? Pediatr Blood Cancer. 2010;54(2):191-192.
18. Bartelink IH, Bredius RG, Belitser SV, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(2):231-241.
19. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(4):472-479.
20. Salinger DH, Vicini P, Blough DK, O'Donnell PV, Pawlikowski MA, McCune JS. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. J Clin Pharmacol. 2010;50(11):1292-300.
21. Rigby RA, Stasinopoulos DM. Using the Box-Cox t distribution in GAMLSS to model skewness and kurtosis. Statistical Modelling. 2006;6:209-229.
22. Otsuka America Pharmaceutical, Inc. Busulfex (busulfan) [package insert]. Tokyo, Japan. http://www.ivbusulfex.com/Otsuka-IVBusulfex-v2AA.pdf. Revised February 2008. Accessed May 30, 2008.
23. Booth BP, Rahman A, Dagher R, et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol. 2007;47(1):101-111.
24. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos. 1999;27(12):1466-1469.
25. Hassan M, Fasth A, Gerritsen B, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant. 1996;18(5):843-850.
26. Vassal G, Fischer A, Challine D, et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood. 1993;82(3):1030-1034.
27. Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther. 2010;87(3):270-271.
28. Vassal G, Michel G, Esperou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61(1):113-123.
29. Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res. 2011;17(21):6867-6877.
30. Meresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant. 1992;10(2):135-141.
31. Zwaveling J, Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant. 2005;35(1):17-23.
32. Johnson L, Orchard PJ, Baker KS, et al. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol. 2008;48(9):1052-1062.
33. Abassi N, Vadnais B, Knutson JA, et al. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol. 2011;51(10):1429-1438.
34. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25-36.
35. Cole M, Boddy AV, Kearns P, et al. Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: how much do we really know? Pediatr Blood Cancer. 2006;46(7):723-727.
36. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28(8):743-751.
37. McCune JS, Batchelder A, Guthrie KA, et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther. 2009;85(6): 615-622.
38. Neely M, Jelliffe R. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol. 2010;50(7):842-847.
39. Barrett JS. Improving pharmacotherapy decision-making. International Innovation. 2011;1.